Capital Fund Management (CFM)’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Capital Fund Management (CFM)’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-103,138	Closed	-$3.3M	–	1722
2022 Q2	$3.3M	Buy	103,138 +7,831	+8%	+$229K	0.03%	641
2022 Q1	$3.3M	Buy	95,307 +82,986	+674%	+$2.48M	0.03%	730
2021 Q4	$361K	Sell	12,321 -2,624	-18%	-$81.3K	﹤0.01%	1498
2021 Q3	$381K	Buy	+14,945	New	+$439K	﹤0.01%	1421
2020 Q1	–	Sell	-6,941	Closed	-$465K	–	2153
2019 Q4	$552K	Buy	6,941 +2,329	+50%	+$138K	﹤0.01%	1345
2019 Q3	$224K	Buy	+4,612	New	+$240K	﹤0.01%	1547
2018 Q4	–	Sell	-44,413	Closed	-$1.69M	–	2314
2018 Q3	$1.69M	Buy	+44,413	New	+$1.97M	0.01%	1189

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital Fund Management (CFM)'s GBT Position: Q3 2022 in Review

Capital Fund Management (CFM) sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 103,138 shares — an estimated $3.3M sold.

Capital Fund Management (CFM) first reported a position in GBT in Q3 2018 and held it in 7 quarters. The position peaked at $3.3M in Q1 2022. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

Capital Fund Management (CFM) reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
Capital Fund Management (CFM) sold 103,138 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $3.3M.
Capital Fund Management (CFM) first reported a position in Global Blood Therapeutics, Inc. in Q3 2018 and held it in 7 quarters.
Capital Fund Management (CFM)'s Global Blood Therapeutics, Inc. position peaked at $3.3M in Q1 2022.
247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2022, filed 14 Nov 2022.